U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H18F3NO2
Molecular Weight 337.3362
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of UFENAMATE

SMILES

CCCCOC(=O)C1=CC=CC=C1NC2=CC=CC(=C2)C(F)(F)F

InChI

InChIKey=JDLSRXWHEBFHNC-UHFFFAOYSA-N
InChI=1S/C18H18F3NO2/c1-2-3-11-24-17(23)15-9-4-5-10-16(15)22-14-8-6-7-13(12-14)18(19,20)21/h4-10,12,22H,2-3,11H2,1H3

HIDE SMILES / InChI

Molecular Formula C18H18F3NO2
Molecular Weight 337.3362
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/26424024 and https://www.researchgate.net/publication/285959437_Evaluation_of_efficacy_and_safety_of_5_butyl_flufenamate_ointment_in_treating_scrotal_eczema

Ufenamate is a topical analgesic. It is indicated for pain and inflammation associated with musculoskeletal and joint disorders. It is a COX inhibitor. Ufenamate is freely soluble in oil and is poorly soluble in water. It is used in the form of ointments or creams. It is manufactured under the brand name Combec in Japan. It is also an ingredient of Fenazol Ointment 5%, used in Japan for the treatment of eczema, dermatitis and herpes zoster.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Fenazol Ointment 5%

Approved Use

It is usually used in the treatment of eczema, dermatitis and herpes zoster.
Primary
Fenazol Ointment 5%

Approved Use

It is usually used in the treatment of eczema, dermatitis and herpes zoster.
Primary
Fenazol Ointment 5%

Approved Use

It is usually used in the treatment of eczema, dermatitis and herpes zoster.
Doses

Doses

DosePopulationAdverse events​
5 % multiple, topical
Recommended
Dose: 5 %
Route: topical
Route: multiple
Dose: 5 %
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Penetration of Ufenamate into Intact, Stripped, or Delipidized Skin Using Different Vehicles.
2015
Patents

Sample Use Guides

In Vivo Use Guide
Apply as a topical preparation at 3% or 3.5%.
Route of Administration: Topical
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:14:37 GMT 2025
Edited
by admin
on Mon Mar 31 18:14:37 GMT 2025
Record UNII
8Z7O7C1SLZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
COMBEC
Preferred Name English
UFENAMATE
INN   JAN   MART.   WHO-DD  
INN  
Official Name English
UFENAMATE [JAN]
Common Name English
Ufenamate [WHO-DD]
Common Name English
ufenamate [INN]
Common Name English
FLUFENAMIC ACID BUTYL ESTER [MI]
Common Name English
BUTYL N-(.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-M-TOLYL)ANTHRANILATE
Systematic Name English
Fenazol
Common Name English
ETOFENAMATE IMPURITY B [EP IMPURITY]
Common Name English
Butyl flufenamate
Common Name English
FLUFENAMIC ACID BUTYL ESTER
MI  
Common Name English
UFENAMATE [MART.]
Common Name English
Butyl 2-[[3-(trifluoromethyl)phenyl]amino]benzoat
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C257
Created by admin on Mon Mar 31 18:14:37 GMT 2025 , Edited by admin on Mon Mar 31 18:14:37 GMT 2025
Code System Code Type Description
FDA UNII
8Z7O7C1SLZ
Created by admin on Mon Mar 31 18:14:37 GMT 2025 , Edited by admin on Mon Mar 31 18:14:37 GMT 2025
PRIMARY
EPA CompTox
DTXSID30867269
Created by admin on Mon Mar 31 18:14:37 GMT 2025 , Edited by admin on Mon Mar 31 18:14:37 GMT 2025
PRIMARY
ChEMBL
CHEMBL2105605
Created by admin on Mon Mar 31 18:14:37 GMT 2025 , Edited by admin on Mon Mar 31 18:14:37 GMT 2025
PRIMARY
SMS_ID
100000076639
Created by admin on Mon Mar 31 18:14:37 GMT 2025 , Edited by admin on Mon Mar 31 18:14:37 GMT 2025
PRIMARY
DRUG CENTRAL
2788
Created by admin on Mon Mar 31 18:14:37 GMT 2025 , Edited by admin on Mon Mar 31 18:14:37 GMT 2025
PRIMARY
NCI_THESAURUS
C152791
Created by admin on Mon Mar 31 18:14:37 GMT 2025 , Edited by admin on Mon Mar 31 18:14:37 GMT 2025
PRIMARY
EVMPD
SUB11375MIG
Created by admin on Mon Mar 31 18:14:37 GMT 2025 , Edited by admin on Mon Mar 31 18:14:37 GMT 2025
PRIMARY
MERCK INDEX
m5433
Created by admin on Mon Mar 31 18:14:37 GMT 2025 , Edited by admin on Mon Mar 31 18:14:37 GMT 2025
PRIMARY Merck Index
CAS
67330-25-0
Created by admin on Mon Mar 31 18:14:37 GMT 2025 , Edited by admin on Mon Mar 31 18:14:37 GMT 2025
PRIMARY
WIKIPEDIA
UFENAMATE
Created by admin on Mon Mar 31 18:14:37 GMT 2025 , Edited by admin on Mon Mar 31 18:14:37 GMT 2025
PRIMARY
MESH
C047051
Created by admin on Mon Mar 31 18:14:37 GMT 2025 , Edited by admin on Mon Mar 31 18:14:37 GMT 2025
PRIMARY
PUBCHEM
5632
Created by admin on Mon Mar 31 18:14:37 GMT 2025 , Edited by admin on Mon Mar 31 18:14:37 GMT 2025
PRIMARY
INN
5349
Created by admin on Mon Mar 31 18:14:37 GMT 2025 , Edited by admin on Mon Mar 31 18:14:37 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> IMPURITY
Related Record Type Details
ACTIVE MOIETY